Updates

Announcements

Director/PDMR Shareholding/TR-1

Sep 8, 2020

To download click here
Placing to raise £6.5 million – update; related party transaction

Sep 7, 2020

The Company announces that admission of the Placing Shares issued in the Placing (as defined in the announcement of 2 September 2020) which was expected to take place at 8.00am on or around 7 September 2020 is now expected to take place at 8.00 am on Tuesday 8 September. The Company also announces it has…
Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund

Sep 3, 2020

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund (“L1”) has converted $150,000 (plus accrued but unpaid interest) of the convertible security issued pursuant to the convertible security deed dated 10 June 2020, details of which were announced by the Company on…
Placing to raise £6.5 million

Sep 2, 2020

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces that in response to investor demand, it has raised £6.5 million, before expenses, via an oversubscribed Placing of 59,090,909 new ordinary shares of 10p each in the Company (“Ordinary Shares”) at a price of 11p (“Placing Price”) per share (the…
TR1 – Notification of major interest in shares by Lanstead Capital

Sep 1, 2020

Click below for information IMM RNS Form TR1 Lanstead 1st September 2020
Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

Jul 27, 2020

ImmuPharma plc (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an important regulatory milestone in preparation for the new optimised international Phase III trial of Lupuzor™ for systemic lupus erythematosus (“SLE”) a potentially life-threatening auto-immune disease. ImmuPharma’s licensing partner for Lupuzor™, Avion Pharmaceuticals LLC (“Avion”), has submitted a Special Protocol…
2020 Annual General Meeting – all Resolutions Passed

Jun 18, 2020

ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance. The Company is pleased to announce that all resolutions were duly passed, by way of a poll. For full announcement click here
Total Share Capital Notification

Jun 16, 2020

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company’s Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting…
ImmuPharma PLC (“ImmuPharma” or the “Company”) Director/PDMR Shareholding

Jun 11, 2020

ImmuPharma (LSE:IMM) (Euronext Growth Brussels: ALIMM), announces that on 11 June 2020, Dr Robert Zimmer, a Director of the Company, transferred 20,000,000 ordinary shares of 10 pence each (“Ordinary Shares”) to Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder. For full information click here
Strategic investments from two specialist US healthcare investors for continued development of ImmuPharma’s therapeutic pipeline

Jun 11, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, is pleased to announce that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million (£4.94 million) comprising an issue of unsecured convertible securities (“Securities”) and associated options (“Options”).…
Notification of Change of Registered Office Address

Jun 5, 2020

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7BL. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (“MAR”).
Notification of Change of AGM Venue

Jun 2, 2020

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that the Company’s Annual General Meeting (AGM) confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU. The COVID-19 Guidance rules still apply, as set out in the announcement issued on…
Notice of AGM and posting of Report & Accounts

May 21, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, confirms that the Annual Report and Accounts for the year ended 31 December 2019, and the Notice of Annual General Meeting has been posted to shareholders. These documents are available, in electronic form, for download on the Company’s website…
TR1 – Notification of major interest in shares by Lanstead Capital

May 18, 2020

Click here for information IMM RNS Form TR1 Lanstead 18 May 2020
ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka

May 14, 2020

ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company provides a progress update on activities around Covid-19. On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new ‘Anti-Infective’ programs, one of which was in ‘Antivirals’. Investigation of the application of the Ureka peptide technologies…
Audited Report & Accounts published on website

Apr 30, 2020

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts (“Report”) for the year ended 31 December 2019, has today been published on the Company’s website. Copies of this Report, including the Notice of Annual General Meeting, will be posted to shareholders in…
FINAL RESULTS For the 12 months ended 31 December 2019

Apr 30, 2020

ImmuPharma plc (LSE:IMM), (Euronext Growth Brussels: ALIMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2019 (the “Period”). Key Highlights (including post Period review) Stable financial performance over the Period – Cash balance of £1.4 million (31 December 2018: £4.9…
ImmuPharma to present live on ‘Investor Meet Company’ platform Tuesday 7 April 2020 | 10.30am (BST)

Apr 6, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman of ImmuPharma, will provide a live presentation relating to the recently announced (30/3/20) £1.5 million Subscription and update on the Company’s R&D programmes, via the ‘Investor Meet Company’ platform. The live…
TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020

Apr 3, 2020

TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020 To view document click here
TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020

Apr 3, 2020

TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020 To view document click here
Subscription to raise £1.5 million to fund expansion of R&D pipeline

Mar 30, 2020

ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, is pleased to announce subscriptions to raise £1.5 million (the “Subscriptions”) through the issue of 15,000,000 new ordinary share of 10 pence each in the Company (“Ordinary Shares”) (the “Subscription Shares”) at a price of 10p per Ordinary Share…

2026 (15)

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

A prodrug is a pharmacologically inactive or much less active compound that is converted inside the body (usually by metabolic enzymes) into the active drug that actually produces the therapeutic effect.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 38 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr. Mauran-Ambrosino obtained her PhD in Chemistry from the Université de Bordeaux as a CIFRE fellow under the co-supervision of Dr. Goudreau. She then conducted postdoctoral research in cell biology at the Centre Hospitalier Universitaire (CHU) Pellegrin in Bordeaux.

In 2018, she joined Ureka, where she established both the Biology and Analytical Chemistry departments. In 2021, she became Chief Scientific Officer of Ureka Pharma. Since 2025, Dr. Mauran-Ambrosino has served as Head of R&D of the ImmuPharma Group.

Dr. Mauran-Ambrosino was a key contributor to the development of several programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 45 years’ international senior level business experience in high growth biotech, healthcare and technology companies. Tim was formerly Chairman of Incanthera plc and 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Director/PDMR Shareholding/TR-1

Placing to raise £6.5 million – update; related party transaction

Conversion of Convertible Security – L1 Capital Global Opportunities Master Fund

Placing to raise £6.5 million

TR1 – Notification of major interest in shares by Lanstead Capital

Submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients

2020 Annual General Meeting – all Resolutions Passed

Total Share Capital Notification

ImmuPharma PLC (“ImmuPharma” or the “Company”) Director/PDMR Shareholding

Strategic investments from two specialist US healthcare investors for continued development of ImmuPharma’s therapeutic pipeline

Notification of Change of Registered Office Address

Notification of Change of AGM Venue

Notice of AGM and posting of Report & Accounts

TR1 – Notification of major interest in shares by Lanstead Capital

ImmuPharma’s efforts in the fight against Covid-19 with Lupuzor™ and Ureka

Audited Report & Accounts published on website

FINAL RESULTS For the 12 months ended 31 December 2019

ImmuPharma to present live on ‘Investor Meet Company’ platform Tuesday 7 April 2020 | 10.30am (BST)

TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020

TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020

Subscription to raise £1.5 million to fund expansion of R&D pipeline